FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2152188246> ?p ?o ?g. }

• W2152188246 endingPage "814" @default.
• W2152188246 startingPage "806" @default.
• W2152188246 abstract "This study was performed to determine the incidence of central venous device-related blood stream infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2 (IL-2).The records of 160 consecutive patients treated at the University of Wisconsin Hospital and Clinics, between June 1990 and June 1997, with moderate dose continuous-infusion IL-2 (IL-2 [1.5-3.0 x 10(6) U/m(2)/day] Hoffman-LaRoche, Nutley, NJ or IL-2 [4.5 x 10(6) U/m(2)/day] Chiron Corporation, Berkley, CA) were reviewed retrospectively. The majority of patients had metastatic melanoma (78 patients) or renal cell carcinoma (70 patients). All of the patients had a surgically implanted central venous device placed before starting IL-2 therapy; 89% of these were cuffed Hickman catheters. Eighty-four patients received 1 mg of warfarin per day as prophylaxis against device-related thrombosis; none received periinsertion prophylactic antibiotics.Twenty-one patients (13%) developed central venous device-related bloodstream infection (DRBSI) during the study period, a rate of 2 DRBSI per 1000 device-days. DRBSIs were associated with the type of immunotherapy given with IL-2 (P = 0.01) and with thrombosis (odds ratio, 4.1; 95% confidence interval, 1.5-11.4; P = 0.008) but not with patient gender, type of cancer, duration of the central device, or site of device placement. Twenty-six patients (16%) developed central venous device-related thrombosis (DRT) during immunotherapy. Low dose warfarin did not appear to prevent thrombosis. Device-related thrombosis was associated with DRBSI but not with patient gender, type of cancer, type of device, duration or location of device, or concomitant immunotherapy.Central venous DRBSI and DRT are significant complications that can occur during moderate dose continuous-infusion IL-2 therapy. The risk of DRBSI appears lower than the risk reported with high dose IL-2 therapy by previous investigators. The risk of DRT appears to be higher than the risk reported for patients with similar devices but not given IL-2. Low dose warfarin did not prevent DRT when started after device placement." @default.
• W2152188246 created "2016-06-24" @default.
• W2152188246 creator A5001986524 @default.
• W2152188246 creator A5011569932 @default.
• W2152188246 creator A5034081251 @default.
• W2152188246 creator A5035289394 @default.
• W2152188246 creator A5050185260 @default.
• W2152188246 creator A5055594290 @default.
• W2152188246 creator A5079184641 @default.
• W2152188246 creator A5091385888 @default.
• W2152188246 date "2001-01-01" @default.
• W2152188246 modified "2023-10-06" @default.
• W2152188246 title "Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2" @default.
• W2152188246 cites W1539497703 @default.
• W2152188246 cites W1862901090 @default.
• W2152188246 cites W1870393419 @default.
• W2152188246 cites W1914396593 @default.
• W2152188246 cites W1936751312 @default.
• W2152188246 cites W1964032970 @default.
• W2152188246 cites W1965975350 @default.
• W2152188246 cites W1967884480 @default.
• W2152188246 cites W1975284023 @default.
• W2152188246 cites W1975312084 @default.
• W2152188246 cites W1985981664 @default.
• W2152188246 cites W1988804370 @default.
• W2152188246 cites W1990032807 @default.
• W2152188246 cites W1990078051 @default.
• W2152188246 cites W2006359096 @default.
• W2152188246 cites W2007872459 @default.
• W2152188246 cites W2011330652 @default.
• W2152188246 cites W2012951244 @default.
• W2152188246 cites W2016292927 @default.
• W2152188246 cites W2032114394 @default.
• W2152188246 cites W2035580122 @default.
• W2152188246 cites W2044889252 @default.
• W2152188246 cites W2053118724 @default.
• W2152188246 cites W2055397536 @default.
• W2152188246 cites W2055584826 @default.
• W2152188246 cites W2060188995 @default.
• W2152188246 cites W2066076015 @default.
• W2152188246 cites W2078687955 @default.
• W2152188246 cites W2083558626 @default.
• W2152188246 cites W2094990599 @default.
• W2152188246 cites W2096491004 @default.
• W2152188246 cites W2104944704 @default.
• W2152188246 cites W2120415712 @default.
• W2152188246 cites W2149724818 @default.
• W2152188246 cites W2155906863 @default.
• W2152188246 cites W2227568616 @default.
• W2152188246 cites W2235510054 @default.
• W2152188246 cites W2262779158 @default.
• W2152188246 cites W2322553446 @default.
• W2152188246 cites W2326245275 @default.
• W2152188246 cites W2405458589 @default.
• W2152188246 cites W2410182080 @default.
• W2152188246 cites W326397834 @default.
• W2152188246 cites W2472595647 @default.
• W2152188246 doi "https://doi.org/10.1002/1097-0142(20010215)91:4<806::aid-cncr1068>3.0.co;2-k" @default.
• W2152188246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11241250" @default.
• W2152188246 hasPublicationYear "2001" @default.
• W2152188246 type Work @default.
• W2152188246 sameAs 2152188246 @default.
• W2152188246 citedByCount "38" @default.
• W2152188246 countsByYear W21521882462012 @default.
• W2152188246 countsByYear W21521882462013 @default.
• W2152188246 countsByYear W21521882462014 @default.
• W2152188246 countsByYear W21521882462017 @default.
• W2152188246 countsByYear W21521882462018 @default.
• W2152188246 countsByYear W21521882462019 @default.
• W2152188246 countsByYear W21521882462020 @default.
• W2152188246 countsByYear W21521882462021 @default.
• W2152188246 crossrefType "journal-article" @default.
• W2152188246 hasAuthorship W2152188246A5001986524 @default.
• W2152188246 hasAuthorship W2152188246A5011569932 @default.
• W2152188246 hasAuthorship W2152188246A5034081251 @default.
• W2152188246 hasAuthorship W2152188246A5035289394 @default.
• W2152188246 hasAuthorship W2152188246A5050185260 @default.
• W2152188246 hasAuthorship W2152188246A5055594290 @default.
• W2152188246 hasAuthorship W2152188246A5079184641 @default.
• W2152188246 hasAuthorship W2152188246A5091385888 @default.
• W2152188246 hasBestOaLocation W21521882461 @default.
• W2152188246 hasConcept C126322002 @default.
• W2152188246 hasConcept C141071460 @default.
• W2152188246 hasConcept C156957248 @default.
• W2152188246 hasConcept C2776301958 @default.
• W2152188246 hasConcept C2779161974 @default.
• W2152188246 hasConcept C2780011451 @default.
• W2152188246 hasConcept C2780868729 @default.
• W2152188246 hasConcept C42219234 @default.
• W2152188246 hasConcept C44249647 @default.
• W2152188246 hasConcept C71924100 @default.
• W2152188246 hasConceptScore W2152188246C126322002 @default.
• W2152188246 hasConceptScore W2152188246C141071460 @default.
• W2152188246 hasConceptScore W2152188246C156957248 @default.
• W2152188246 hasConceptScore W2152188246C2776301958 @default.
• W2152188246 hasConceptScore W2152188246C2779161974 @default.
• W2152188246 hasConceptScore W2152188246C2780011451 @default.
• W2152188246 hasConceptScore W2152188246C2780868729 @default.

• next